Immucell (ICCC) Change in Account Payables (2010 - 2014)
Immucell's (ICCC) quarterly Change in Account Payables came in at -$10547.0 in Q3 2014, up 86.45% YoY from -$5656.9 in Q3 2013, and down 59.56% on a QoQ basis from -$6610.0 in Q2 2014.
Immucell (ICCC) Change in Account Payables (2010 - 2014) Analysis & Trends
Immucell (ICCC) has 5 years of Change in Account Payables data on file, last reported at -$10547.0 in Q3 2014.
- Quarterly Change in Account Payables rose 86.45% year-over-year to -$10547.0 in Q3 2014, while the trailing twelve-month figure through Sep 2014 was $39864.0 (up 155.66% YoY) and the FY2013 annual result came in at -$95503.0, down 195.46% from the prior year.
- Change in Account Payables retreated to -$10547.0 in Q3 2014, from -$6610.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $79429.0 in Q1 2012 to a low of -$93350.0 in Q2 2012.
- A 5-year average of $3233.5 and a median of $21992.0 in 2014 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2011 — Change in Account Payables jumped 139.69% — and 2013, when it sank 241.33%.
- Tracing ICCC's Change in Account Payables over 5 years: stood at -$69877.0 in 2010, then jumped by 139.69% to $27733.0 in 2011, then soared by 112.41% to $58909.0 in 2012, then sank by 40.54% to $35029.0 in 2013, then sank by 130.11% to -$10547.0 in 2014.
- The last three Change in Account Payables figures came in at -$10547.0 (Q3 2014), -$6610.0 (Q2 2014), and $21992.0 (Q1 2014), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | -10,547.00 |
| Sep 30, 2014 | -10,547.00 |
| Jun 30, 2014 | -6,610.00 |
| Jun 30, 2014 | -6,610.00 |
| Mar 31, 2014 | 21,992.00 |
| Mar 31, 2014 | 21,992.00 |
| Dec 31, 2013 | 35,029.00 |
| Dec 31, 2013 | 35,029.00 |
| Sep 30, 2013 | -77,817.00 |
| Sep 30, 2013 | -77,817.00 |
| Jun 30, 2013 | 15,795.00 |
| Jun 30, 2013 | 15,795.00 |
| Mar 31, 2013 | -68,510.00 |
| Mar 31, 2013 | -68,510.00 |
| Dec 31, 2012 | 58,909.00 |
| Dec 31, 2012 | 58,909.00 |
| Sep 30, 2012 | 55,059.00 |
| Sep 30, 2012 | 55,059.00 |
| Jun 30, 2012 | -93,350.00 |
| Jun 30, 2012 | -93,350.00 |